New and Emerging Drug Therapies for PE

Significance of penile hypersensitivity in premature ejaculation. Corona G, Rastrelli G, Limoncin vardenafil hcl 10mg E, Sforza A, Jannini EA, Maggi M.

Expected duration

A multinational population survey of intravaginal ejaculation latency time. A five-nation survey to assess the distribution of the intravaginal ejaculatory latency time among the general male population. Characteristics of men who are bothered by rapid ejaculation: results from clinical intake surveys. Advances in understanding and treating premature ejaculation. Frequency of etiological factors among patients with acquired premature ejaculation: prospective, observational, single-center study. Interplay between premature ejaculation and erectile dysfunction: a systematic review and meta-analysis.

Association between lifelong premature ejaculation and polymorphism of tryptophan hydroxylase 2 gene in the Han population.

From Mayo Clinic to your inbox

In a trial conducted in 2020, the effectiveness of TPTNS treatment was compared to sham therapy in a group of 60 men with PE. They underwent 30-min sessions of either TPTNS or sham therapy once a week. At the conclusion of the 12-week treatment period, the average IELT values increased from 40.4 s to 51.25 s for patients receiving TPTNS, while for those treated with sham therapy, the values went from 37.9 s to 42.5 s (P = 0.030) [52]. This study revealed an improvement in IELT scores in the Sham group, even though no electrical current was applied. This suggests that the contact of the TPTNS probe with the body may have induced a placebo effect.

Basic questions to ask your doctor

There were no statistically significant differences observed between patients treated with TPTNS or Sham in terms of the percentage change in IELT scores from pre-to-post-procedure (0.38 ± 0.47 vs. 0.23 ± 0.67, P = 0.415). However, it’s important to note that a major limitation of this study was the absence of randomization, potentially introducing bias in participant selection. The initial outcomes of TPTNS in treating PE appear conflicting, highlighting the need for randomized controlled studies involving large patient cohorts. In recent years, a new approach to treating PE has emerged, involving the use of a masturbation aid device in conjunction with behavioral techniques. The 5-HT2C receptor gene Cys23Ser polymorphism influences the intravaginal ejaculation latency time in Dutch Caucasian men with lifelong premature ejaculation.

See also

TPTNS therapy has found extensive application in pelvic floor physiotherapy [47]. The underlying principle of electrostimulation therapy is rooted in the intricate sensorimotor function of the posterior tibial nerve, originating from T4–S3 roots. While the emission phase of ejaculation is primarily governed by stimuli from the T12–L1 area [48], the expulsion phase is predominantly regulated at the S2–S4 level [49, 50]. Consequently, TPTNS has the potential to inhibit both the emission (through the sympathetic system) and expulsion (through the parasympathetic–somatic ejaculation system) phases of ejaculation. In a phase II trial, TPTNS was assessed as a novel treatment approach for PE.

Topical Treatments for Premature Ejaculation

Eleven patients with PE underwent TPTNS sessions lasting 30 min, three times a week for 12 weeks. In total, 6 out of 11 (54%) patients who completed the 12-week treatment period exhibited a three-fold increase in IELT compared to baseline (P = 0.037). Only two patients reported complications, such as constipation (n = 1) and a sensation of heat in the leg (n = 1). Importantly, no reported adverse effects led to a change in therapy adherence. However, it is important to note that this study has significant limitations, including a very low number of participants, the absence of a control group, and a lack of randomization [51]. Effects of paroxetine on intravaginal ejaculatory latency time in Egyptian patients with lifelong premature ejaculation as a function of serotonin transporter polymorphism. Study of the link between dopamine transporter gene polymorphisms and response to paroxetine and escitalopram in patients with lifelong premature ejaculation.

• Dapoxetine is contraindicated with certain medications and health conditions.
• Topical creams should be used sparingly to prevent partner numbness.
• SSRI treatment may cause emotional blunting or decreased libido.
• Tramadol's risk of dependency requires careful medical supervision.
• Mechanical devices can provide temporary ejaculation delay.
• Behavioral training involves specific sex exercises for control.
• Mindfulness and relaxation techniques benefit PE management.
• Proper diagnosis is essential to rule out underlying disorders.
• Incorporate partner feedback to improve treatment results.
• Avoid abrupt discontinuation of prescribed medication.
• Lifestyle modifications can include weight management.
• Ongoing research aims to develop more effective PE treatments.

Possible role of serum testosterone, gonadotropins and prolactin in patients with premature ejaculation. The relationship between premature ejaculation and hyperthyroidism. Sihotang RC, Alvonico T, Taher A, Birowo P, Rasyid N, Atmoko W. Premature ejaculation in patients with lower urinary tract symptoms: a systematic review.

Scheduling an Appointment

However, the available drug treatments for PE come with limited effectiveness, a range of adverse effects, and a high rate of discontinuation. A definitive cure for PE, or at least therapies allowing for spontaneity during intercourse, remain elusive. Encouragingly, data from studies utilizing newly developed technological techniques and medical devices in PE treatment show promise. Solutions that are drug-free, entail minimal adverse effects, and permit spontaneity during intercourse are on the horizon. However, additional clinical studies would be beneficial in confirming the effectiveness of these therapies, potentially establishing them as possible alternatives to pharmacological PE treatments.

Sertraline (Zoloft)

This is a review article with no original scientific data. Althof S. Prevalence, characteristics and implications of premature ejaculation/rapid ejaculation. Diagnostic and statistical manual of mental disorders: DSM-5. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second International Society for Sexual Medicine AdHoc Committee for the definition of premature ejaculation. Chronic prostatitis in premature ejaculation: a cohort study in 153 men.

• Dapoxetine has a rapid onset, typically within 1-3 hours.
• Topical anesthetics should be applied in small amounts to avoid overdose.
• SSRI side effects may include sleep disturbances or gastrointestinal upset.
• Tramadol can cause dizziness, dry mouth, and nausea as side effects.
• Behavioral techniques teach men to recognize early signs of ejaculation.
• Pelvic floor training can enhance ejaculatory control.
• Counseling sessions help address performance anxiety and stress.
• Medications should be used as prescribed to minimize risks.
• Some men respond better to combination therapies.
• Abstaining from excessive masturbation may help in some cases.
• Lifestyle changes and psychological support are important adjuncts.
• Any medication or supplement should be discussed with a healthcare professional.

The distribution of patients who seek treatment for the complaint of ejaculating prematurely according to the four premature ejaculation syndromes. Mondaini N, Fusco F, Cai T, Benemei S, Mirone V, Bartoletti R.

Dapoxetine treatment in patients with lifelong premature ejaculation: the reasons of a “Waterloo”. Towards evidence-based drug treatment research on premature ejaculation: a critical evaluation of methodology. McMahon CG, Porst H. Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation. Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation. Real-life use of the eutectic mixture lidocaine/prilocaine spray in men with premature ejaculation.

• Dapoxetine used before sex provides quick relief from PE.
• Topical anesthetic applications should be tailored to individual needs.
• SSRIs may cause delayed orgasm or decreased sexual desire.
• Tramadol is an alternative but carries substantial risks.
• Training with behavioral techniques can lead to lasting improvements.
• Fatigue and stress reduction support sexual performance.
• Pelvic floor strengthening is a natural method to control ejaculation.
• Psychological support addresses underlying emotional issues.
• Mechanical aids are an option for some men.
• Combining medications with psychotherapy enhances efficacy.
• Avoid self-medicating without professional advice.
• Consistent follow-up optimizes long-term management.

Abu El-Hamd M. Effectiveness and tolerability of lidocaine 5% spray in the treatment of lifelong premature ejaculation patients: a randomized single-blind placebo-controlled clinical trial.

• Dapoxetine is taken as needed, usually 1-3 hours before sex for rapid action.
• Topical anesthetics should be used sparingly to avoid numbness of partner.
• SSRIs may cause side effects like nausea, dizziness, or decreased libido.
• Tramadol carries potential for abuse and should only be used under medical supervision.
• Daily use of certain medications may be recommended for persistent PE.
• Psychological counseling helps address performance anxiety contributing to PE.
• Pelvic floor exercises improve control and delay ejaculation naturally.
• Partner involvement in therapy can improve treatment adherence.
• Discontinuing medication abruptly may cause withdrawal symptoms or rebound.
• For some men, combining therapy with lifestyle changes yields better results.
• Over-the-counter remedies should be approached cautiously and discussed with a doctor.
• Research continues into new pharmacological and non-pharmacological treatments.

Efficacy and safety of behavioral therapy for premature ejaculation: protocol for a systematic review. Pelvic floor muscle rehabilitation for patients with lifelong premature ejaculation: a novel therapeutic approach. Pelvic muscle floor rehabilitation as a therapeutic option in lifelong premature ejaculation: long-term outcomes. Transcutaneous neuromuscular electrical stimulation may be beneficial in the treatment of premature ejaculation. Transcutaneous functional electrical stimulation — a novel therapy for premature ejaculation: results of a proof of concept study. A Novel, on-demand therapy for Lifelong Premature Ejaculation using a Miniature Trans-Perineal Electrical Stimulator, the vPatch® - as-treated analysis. Peyronnet B, Amarenco G, Kerdraon J, Cornu JN, Gamé X.

Phosphodiesterase Type 5 Inhibitors

In a multicenter randomized clinical trial utilizing a parallel group design to assess the effectiveness of the electronic masturbation device known as Myhixel © (MYHIXEL, Seville, Spain) in PE treatment, Rodriguez et al. assigned 52 patients to two treatment groups, with only bayer vardenafil 40 completing the study. All patients underwent an 8-week Sphincter Control Training program. The sole distinction between the groups was the inclusion of the Myhixel © device. The primary metric was the “fold increase” in IELT.

Premature ejaculation prognosis

At the conclusion of the 8-week treatment, the geometric means of IELT demonstrated more favorable outcomes for the device group, albeit without statistical significance (P = 0.11) (an increase of 30 s versus 90 s from baseline in the exercise-only and device groups, respectively). Notably, in the device group, the fold increase in IELT was significantly higher compared to the exercise-only group, at 4.27 versus 2.09, respectively (P = 0.001) [53] (See Table 1 for comparison between the new technologies). While there are treatments for PE that are actually, clinically proven, scientifically significant and FDA cleared (i.e behavioral therapies, topical anesthetics, and certain medications and medical devices), there are also numerous devices and products on the market that claim to treat or prevent PE but lack scientific evidence to support their efficacy (i.e Morari device- #how-it-works, Vaacum constriction devices, male vibrators). It’s crucial to approach any device claiming to treat PE with skepticism and caution unless there is robust scientific evidence supporting its efficacy and safety. Currently, the standards of care in PE treatment are mainly SSRIs and topical anesthetics. Transcutaneous posterior tibial nerve stimulation: ready for prime time. Giuliano F. Neurophysiology of erection and ejaculation. Puppo V, Puppo G.

Treatments for premature ejaculation

Prevalence and correlates of premature ejaculation in a primary care setting: a preliminary cross-sectional study. Premature ejaculation and erectile dysfunction prevalence and attitudes in the Asia-Pacific region. Prevalence of the complaint of ejaculating prematurely and the four premature ejaculation syndromes: results from the Turkish Society of Andrology Sexual Health Survey. An update of the International Society of Sexual Medicine’s Guidelines for the diagnosis and treatment of premature ejaculation (PE). Waldinger MD, Quinn P, Dilleen M, Mundayat R, Schweitzer DH, Boolell M. Comprehensive review of the anatomy and physiology of male ejaculation: premature ejaculation is not a disease. Transcutaneous electric nerve stimulation to treat patients with premature ejaculation: phase II clinical trial.